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Abstract
Background: Aspirin remains the mainstay of anti-platelet therapy in cardiac patients.
However, if a patient is allergic to aspirin and dual anti-platelet therapy is indicated — such
as with percutaneous coronary intervention (PCI), then there is no clear guidance. One
possibility is aspirin desensitization. A variety of protocols exist for the rapid desensitization of
patients with aspirin allergy. The aim of this survey was to assess current knowledge and
practice regarding aspirin desensitization in the UK.
Methods and results: We conducted a UK wide survey of all UK 116 PCI centers and
obtained complete responses from 40 (35.4%) centers. Of these, just 7 (17.5%) centers had
previously desensitised patients; 29 (87.9%) centers suggested a lack of a local protocol
prevented them from desensitizing, with 10 (30.3%) unsure of how to conduct desensitization.
Only 5 (12.5%) centers had a local policy for aspirin desensitization although 25 (64.1%)
units had a clinical strategy for dealing with aspirin allergy; the majority (72%) giving higher
doses of thienopyridine class drugs.
Conclusions: In the UK, there appears to be no consistent approach to patients with aspirin
allergy. Patients undergoing PCI benefit from dual anti-platelet therapy (including aspirin),
and aspirin desensitization in those with known allergy may facilitate this. Sustained effort
should be placed on encouraging UK centers to use desensitization as a treatment modality
prior to PCI rather than avoiding aspirin altogether. (Cardiol J 2013; 20, 2: 134–138)
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Introduction
Aspirin or acetylsalicylic acid (ASA) is widely
used in cardiology patients, however, up to 20% are
intolerant, with true allergy affecting 0.5–2.4% of
patients [1, 2]. ASA acts primarily through irrevers-
ible inhibition of cyclooxygenase-1 (COX-1), pre-
venting conversion of arachidonic acid to thrombox-
ane (TxA2) and thus inhibiting platelet aggregation.
The production of TxA2 can be completely inhibit-
ed through 75 mg/day dosing of aspirin [3].
In patients undergoing percutaneous coronary
intervention (PCI), dual anti-platelet therapy with
aspirin, and an ADP-receptor antagonist (such as
clopidogrel) has been shown to reduce the incidence
of thrombotic events compared to aspirin alone [3–5].
The therapeutic goal is to reduce ischemic events
and minimise bleeding complications. Despite the
135
Andrew R. Chapman et al., Aspirin desensitization
www.cardiologyjournal.org
development of newer agents such as prasugrel and
ticagrelor, aspirin remains the first antiplatelet of
choice. Where patients are intolerant, non-aspirin
based dual anti-platelet combinations may be uti-
lised, but there is only a limited evidence base for
this [6].
Aspirin allergy
Allergy to aspirin may be broadly categorized
into having either a pharmacological or immunolo-
gical basis. The pharmacologic ‘allergy’ is the direct,
symptomatic result of COX-1 inhibition, whereas
a true immunological allergic response is due to pro-
duction of aspirin-antigen specific immunoglobu-
lin E (IgE). Allergy to aspirin may manifest as aspirin-
-exacerbated respiratory disease (AERD), cutane-
ous, mixed or systemic reactions.
AERD is a triad of asthma, aspirin sensitivi-
ty and rhinitis with or without nasal polyps, and
may also be known as aspirin intolerant asthma.
Respiratory reactions to asthma typically occur
within the first few hours of ingestion, with
wheeze and shortness of breath accompanied by
rhinitis, conjunctival irritation and facial flushing.
The majority of AERD patients may be success-
fully desensitized [7].
Cutaneous reactions to asthma are comprized
of urticaria and angioedema. Patients are more like-
ly to react to aspirin when urticaria is active. 21–
–30% of those with chronic idiopathic urticaria will
experience heightened urticaria when exposed to
aspirin [8–10]. Patients with a specific diagnosis of
chronic idiopathic urticaria are not thought to be
appropriate for desensitisation, however, patients
with urticaria as part of a cutaneous reaction may
be considered for desensitization [10]. One mecha-
nism of preventing angioedema or urticarial symp-
toms as a result of non-steroidal anti-inflammatory
drugs (NSAIDs) administration is the use of leukot-
riene receptor antagonists. When angioedema oc-
curs alongside hypotension this should be consid-
ered a systemic not cutaneous insult.
The systemic reactions to aspirin administra-
tion tend to be most severe. They occur within
minutes of administration and include classical fea-
tures of anaphylaxis such as hypotension, laryngeal
edema, pruritis, tachypnoea and may evolve to
cause loss of consciousness. There is no consen-
sus within the literature as to whether systemic
reactions should be desensitized [10–12]. General-
ly, given the potential for a life-threatening event,
such patients are not desensitized.
It is vital to obtain a complete drug history from
patients considered to be ‘allergic’ to aspirin. If a re-
action occurred on first exposure to the drug, this is
likely to represent a pharmacological anaphylactoid
response. Whereas, if a reaction occurred on second
exposure it is more likely that this is IgE mediated
and hence a true anaphylactic episode. Adverse
reactions to other NSAIDs should be documented
as cross-reactivity is known to occur.
Aspirin desensitization
Desensitization can be described as the tem-
porary induction of a tolerance to a drug antigen. In
the case of aspirin, the mechanisms are poorly un-
derstood. It is thought that desensitization occurs
as a result of decreased leukotriene production,
down-regulation of cystienyl leukotriene receptors
and hence a decrease in histamine and tryptase re-
lease from mast cells [10–13].
Aspirin desensitization has been shown to be
both safe and effective when carried out under con-
trolled conditions. There are several published pro-
tocols which have established safe procedures to
desensitize patients with known aspirin allergy [9,
13, 14], but no single guideline has been interna-
tionally adopted (Table 1). In principle, a patient is
‘challenged’ with incremental dose increases over
fixed time periods, until a positive reaction to aspi-
rin is noted, characterized typically by a reduction
in FEV1 of > 20%, combined with naso-ocular
symptoms [13]. Symptomatic treatment is initiat-
ed at this stage, with the dose repeated until the
patient becomes tolerant. Provided a desensitized
patient does not interrupt regular aspirin dosing, the
desensitized state will persist [7]. The dose at which
desensitization is commenced is dependent on risk
stratifying given their history.
It is recommended that beta-blockers are
stopped 24 h prior to an aspirin challenge as a pre-
cautionary measure [15] as it is thought that they
may increase sensitivity to allergens, and hence
provoke a more significant immune response [16–
–20]. In addition, beta-blockers can decrease the re-
sponse to adrenaline — first line treatment for ana-
phylaxis [15, 16, 19]. In those taking angiotensin
converting enzyme (ACE) inhibitors undergoing de-
sensitization, a higher rate of systemic reactions
have been observed and hence it is suggested that
these are also omitted [19, 21].
Methods
We conducted a UK based survey of all 116 PCI
centers as identified in the British Cardiovascular
Intervention Society audit database (www.BCIS.org).
A brief eight point questionnaire was designed
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and tested for face validity by an expert panel
before being posted to the lead cardiologist of
each unit (Table 2). After 4 weeks the question-
naire was resent to departments which had not
responded. Participants were notified of our in-
tention to publish results to guide future practice
via a covering letter, and implied consent was
taken with all responses. We excluded any incom-
plete responses.
Results
Of 116 units posted a questionnaire, we re-
ceived 41 (35.5%) responses. There was 1 exclu-
sion as the center no longer performed PCI, leav-
ing 40 questionnaires for analysis. Responses were
obtained from centers in Scotland (5/8), England
(33/101), Northern Ireland (2/4) and Wales (1/3).
Complete results are displayed in Table 2.
Discussion
This survey has demonstrated wide variation
in clinical practice. A minority of cardiac units had
conducted aspirin desensitization in the past year,
and even in those units who did, only a very small
number of patients underwent desensitization.
Those units that have not conducted desensitiza-
tion seem to suggest that primarily this is down to
a lack of a local protocol (29 centers, 87.9%), in ad-
dition to a lack of understanding (10 centers, 30.3%).
Only a small number of units had concerns regard-
ing the safety of desensitization.
The majority of units had no local protocol for
desensitizing patients with a known aspirin aller-
gy, and most of these were unsure of which parti-
cular responses they would consider desensitizing.
Of interest, 12 units (30%) would consider desen-
sitizing those with a previous systemic reaction.
Those who had previously desensitized patients
gave thorough responses when asked about parti-
cular patient responses, with one center rapidly de-
sensitizing patients with AERD or previously do-
cumented anaphylaxis on an intensive care unit.
In patients with known aspirin allergy, most
units (whilst not able to desensitize) will attempt
to compensate for the lack of aspirin through the
use of other agents, primarily use of higher doses
of ADP-receptor antagonists such as clopidogrel
(10/41), prasugrel (7/41) or ticagrelor (1/41). One
unit responded by mentioning GP IIb/IIIa receptor
antagonists such as tirofiban. Whilst increased dos-
es of these drugs may increase the likelihood of
suppressing thrombotic events, this area has not
been extensively studied when compared to known
benefits of dual anti-platelet therapy, and there is
only limited data on patient outcomes with this ap-
proach.
Whilst the majority of units would consider
desensitizing either elective PCI (7 units, 17.9%)
Table 1. Available protocols for aspirin desensitisation.
Indications Doses of aspirin [mg] Dose interval Monitoring Duration
intervals1
Silberman Acute CAD 5, 10, 20, 40, 75 30 min 30 min 2.5 h
et al. [14]  and hypersensitivity
Szczeklik, High risk patients Day 1: placebo/ 3 hourly 1 hourly2 72 h
Stevenson [22] challenge protocol /placebo/placebo (over 3 days)
Day 2: 30/60/120
Day 3: 150/325/650
Wong et al. [23] Cutaneous 0.1, 0.3, 10, 30 First 4 doses 1 hourly2 2.25 h
reactions  40, 81, 162, 325 × 15 min
Subsequent
doses × 25 min
Schafer, Gore [9] Cutaneous Placebo/placebo, 1 h 1 h 6 h
reactions placebo/150 mg,
placebo/325 mg, 325 mg/
/325 mg, placebo/placebo
Stevenson, Simon AERD 20.25, 40.5, 60, 75, 81, 3 h 1 hourly2 48 h
‘Scripps Clinic’ [24] 101.25, 162.5, 325
Hope et al. [25] AERD 30, 45, 60, 100, 150, 3 h 1 hourly2 48/72 h
325, 650
1 Typically involves HDU monitoring, and pulse/BP/FEV1 at pre-determined intervals; 2or when symptomatic; CAD — coronary artery disease;
AERD — aspirin exacerbated respiratory disease
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or both elective and post-myocardial infarction
(18 units, 46.1%), 16 (41%) units would not consider
desensitising any patients. When asked about omit-
ting beta-blockers or ACE inhibitors, a wide varie-
ty of responses were given and knowledge in this
area would appear inconsistent. This has obvious
implications to cardiac patients, particularly in the
context of a recent myocardial infarction. Those that
stated they would hold beta-blockers or ACE inhi-
bitors did so in the context of patients with preserved
left ventricular function, a lack of ongoing ischemia,
patients with asthma or previous anaphylaxis who
were considered to be high risk, or for those hav-
ing elective PCI.
We have found a wide variety of current prac-
tice throughout the UK, and further to this there
seems to be a lack of a consistent approach to the
management of patients with aspirin allergy who are
Table 2. Results from questionnaire based survey of 40 percutaneous coronary intervention (PCI) units.
Has your unit administered an aspirin desensitization regimen before? 40 (100%)
Yes 7 (17.5%)
If yes, how many patients per year? 40 (100%)
1 4 (10%)
2–6 3 (7.5%)
7–12 0 (0%)
> 12 0 (0%)
If no, is this due to: 33(100%)
No local desensitization protocol? 29 (87.9%)
Unsure of how to complete desensitization? 10 (30.3%)
Concerns regarding the safety of desensitization? 3 (9%)
Not clinically indicated? 4 (12.1%)
Other (specified) 0 (0%)
Does your unit have a desensitization policy for patients with aspirin allergy? 40 (100%)
Yes 5 (12.5%)
Which allergies would you consider desensitizing? 40 (100%)
None 11 (27.5%)
Cutaneous 11 (27.5%)
Aspirin exacerbated respiratory disease 8 (20%)
Systemic reactions 12 (30%)
Mixed reactions 7 (17.5%)
Unsure 17 (42.5%)
Does your unit have a clinical strategy for patients requiring PCI with an aspirin allergy? 39 (100%)
Yes 25 (64.1%)
If yes, what strategy? 25(100%)
ADP-receptor antagonist monotherapy (e.g. clopidogrel) 18 (72%)
GP IIb/IIIa receptor antagonists (e.g. tirofiban) 1 (4%)
Aspirin desensitization if scheduled procedure 1 (4%)
No information given 5 (20%)
Would you consider elective desensitization in the following patients? 39 (100%)
Elective PCI only 7 (17.9%)
Post-myocardial infarction PCI only 0 (0%)
All PCI 18 (46.1%)
Neither 16 (41%)
If you answered post-myocardial infarction PCI or both, would you stop beta-blockers 18 (100%)
or ACE inhibitors?
Yes 6 (33.3%)
No 7 (33.3%)
Unsure 4 (22%)
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to undergo PCI. This may in part be due to limited
knowledge of this specialized area.
Limitations of the study
This was a self-reported survey and therefore
there is a risk that the responses did not accurately
reflect local practices, however, this is unlikely as
questionnaires were sent to the clinical lead for the
cardiac catheterization lab in each center. Whilst
the response rate was low, responses were re-
ceived from all areas in the UK. Furthermore, it
is likely that additional responses would just add
to the variation in clinical practice that has been
demonstrated and would not greatly affect the
outcomes of this study.
Conclusions
Based on the data presented, the use of aspi-
rin desensitization in the UK appears to be low.
There appears to be a need to address this appar-
ent lack of awareness regarding aspirin desensiti-
zation as a therapeutic modality, and thereby in-
crease its availability to patients currently unable
to tolerate and potentially benefit from conventional
and evidence based dual anti-platelet therapy.
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